Screener
Alamar Biosciences ALMR EMEA — Revenue
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alamar Biosciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Alamar Biosciences’s 10-Q, filed May 8, 2026.
- Filed
- May 8, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-213424
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| United States | $14,905 | $9,469 |
| Europe, Middle East and Africa (excluding United Kingdom) | 3,972 | 1,422 |
| United Kingdom | 3,462 | 1,730 |
| Asia-Pacific | 2,409 | 450 |
| Americas (excluding United States) | 1,287 | 20 |
| Total | $26,035 | $13,091 |
Item 1. Financial Statements
FAQ
- What is Alamar Biosciences's EMEA — revenue?
- Alamar Biosciences (ALMR) reported EMEA — revenue of $3.97M in Q1 2026.
- What does EMEA — revenue mean?
- This metric represents the total revenue generated from contracts with customers located within the Europe, Middle East, and Africa (EMEA) region, net of any assessed sales or value-added taxes. It serves as a key indicator of the company's market penetration and commercial success in these specific international territories. By isolating this geographic revenue, stakeholders can evaluate the adoption rate of the company's proteomics platform and NULISA technology outside of its primary domestic market.
Ask your AI about Alamar Biosciences's emea — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude